XML 359 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statement of Cash Flows - COP ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Cash flows from operating activities:      
Net income before income tax $ 3,487,550 $ 6,274,371 $ 8,520,297
Reconciliation of net income before taxes and net cash (used) provided by operating activities:      
Depreciation of tangible assets and right-of-use assets 557,062 559,875 886,949
Amortization of intangible assets 594,109 530,625 559,403
Impairment losses on loans and other accounts receivable 4,802,074 3,179,476 4,551,160
Net interest income (6,286,974) (7,738,637) (12,728,861)
Accrued dividends (126,274) (119,888) (159,122)
Net gains on sales of non-current assets held for sale (47,994) (9,687) (33,046)
Gain on sale of property plant and equipment for own-use (344,742) (140,229) (23,436)
Loss on sale of investment property 22,177 17,305 9,964
Gain on biological assets (10,467) (13,041) (34,635)
Valuations and interest from concession agreements (3,916,465) (5,136,704) (4,158,048)
Foreign exchange losses (gains) (2,253,925) 1,825,718 (87,235)
Profit of equity accounted on investments in associates and joint ventures (371,397) (372,777) (300,217)
Net (gains) or losses on fair value adjustments of:      
Derivatives 2,581,132 (1,529,855) (798,187)
Non-current assets held for sale 268 76 3,874
Investment properties (84,958) (55,930) (22,775)
Biological assets (18,601) (56,859) (28,546)
Changes in operating assets and liabilities:      
Trading assets (2,764,761) 545,497 696,846
Other accounts receivable (975,734) (2,376,815) (617,745)
Derivatives (2,091,326) 1,379,945 43,979
Other assets (78,251) 121,837 (316,886)
Other liabilities and provisions 1,434,088 462,871 1,912,622
Employee benefits (27,517) 7,928 (8,388)
Loans (7,600,446) (27,840,725) (16,024,938)
Customer deposits 15,352,172 17,835,153 6,916,177
Interbank borrowings and overnight funds 5,881,960 (1,352,653) 3,218,258
Borrowings from development entities (240,498) 408,018 (1,898)
Borrowings from banks and others (3,864,609) 8,719,782 3,509,251
Interest received 26,104,288 16,944,928 19,423,325
Interest paid (21,529,719) (10,608,415) (7,091,527)
Interest paid on leases (202,362) (146,275) (168,966)
Income tax paid (1,974,359) (1,537,039) (1,746,019)
Net cash provided (used in) operating activities 6,005,501 (222,124) 5,901,630
Cash flows from investing activities:      
Acquisition of property, plant and equipment for own use and operating lease (589,071) (519,368) (664,506)
Acquisition of investment property (163) (2,266) (876)
Additions of cost of biological assets (26,118) (28,368) (27,213)
Capitalization and payments in concession contracts 853,778 452,612 (994,639)
Additions of others intangibles assets (683,457) (598,177) (569,920)
Acquisition of investments at FVOCI (24,353,596) (21,008,926) (41,292,437)
Proceeds from sale of investments at FVOCI 25,675,840 23,492,758 35,457,164
Proceeds from sale of own property and equipment 76,699 72,991 76,726
Proceeds from sale of investment properties 111,542 76,306 67,463
Proceeds from sale of biological assets 37,144 40,624 58,083
Proceeds from sale of non-current assets held for sale 61,652 41,635 76,846
Purchases of financial assets at amortized cost (8,016,108) (6,914,604) (5,743,019)
Redemptions of financial assets at amortized cost 8,219,792 6,403,372 6,589,962
Dividends received from investments 477,568 411,369 368,964
Acquisition of investments in associates (2,433) (7,267) (4,539)
Capitalized leasing cost (132) (690)  
Proceeds from sale of investments in associates   2,645,914  
Deconsolidation of entities (2,290)    
Discontinued operation   (17,570,390)  
Net cash Provided (used) in investing activities 1,840,647 (13,012,475) (6,601,941)
Cash flows from financing activities:      
Dividends paid to shareholders (766,537) (414,267) (1,230,841)
Dividends paid to non-controlling interest (915,933) (615,177) (913,356)
Issuance of debt securities 2,609,994 695,136 2,931,280
Payment of outstanding debt securities (4,072,742) (7,837,898) (1,631,318)
Leases (391,667) (383,472) (472,084)
Redemption of preferred shares     (29,751)
Equity transaction   (15,014) 120
Net cash used in financing activities (3,536,885) (8,570,692) (1,345,950)
Effect of foreign currency changes on cash and cash equivalents (2,744,259) 3,588,921 4,663,555
Decrease in cash and cash equivalents from discontinued operations   (1,393,602)  
Increase (decrease) in cash and cash equivalents 1,565,004 (19,609,972) 2,617,294
Cash and cash equivalents at beginning of year 17,032,857 36,642,829 34,025,535
Cash and cash equivalents at end of year $ 18,597,861 $ 17,032,857 $ 36,642,829